Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ638,56390,16
KB783783,5-0,95
PKN8383,06-0,12
Msft0,78
Nokia4,54754,5510,90
IBM-0,83
Daimler AG79,5779,590,84
PFE-1,30
15.06.2021 9:56:59
Indexy online
AD Index online
select
AD Index online
 

  • 14.06.2021
Exelixis (EXEL.O, NASDAQ Cons)
Závěr k 14.6.2021 Změna (%) Změna (USD) Objem obchodů (ks)
22,76 -0,96 -0,22 1 188 624
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 15.06.2021
Popis společnosti
Obecné informace
Název společnostiExelixis, Inc.
TickerEXEL
Kmenové akcie:Ordinary Shares
RICEXEL.O
ISIN-
Poslední známé roční výsledky31.12.2020
Poslední známé čtvrtletní výsledky31.03.2021
Počet zaměstnanců k 31.12.2020 773
Akcie v oběhu k 26.04.2021 313 387 205
MěnaUSD
Konstituent indexůS&P 400 Mid Cap
Kontaktní informace
Ulice1851 Harbor Bay Pkwy
MěstoALAMEDA
PSČ94502-3016
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 508 377 000
Fax16508378300

Business Summary: Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.
Financial Summary: BRIEF: For the 13 weeks ended 31 March 2021, Exelixis, Inc.revenues increased 19% to $270.2M. Net income decreased 97%to $1.6M. Revenues reflect U.S segment increase of 17% to$230M, Japan segment increase from $1.3M to $6.5M. Netincome was offset by Other Research and developmentincrease of 52% to $146.9M (expense), Other selling generaland administration increase of 48% to $80.1M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in Biotechnology
NAICS2007Medicinal & Botanical Mfg
NAICS2007In-Vitro Diagnostic Substance Mfg
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Medicinal and Botanical Manufacturing
NAICS1997InVitro Diagnostic Substance Manufacturing
NAICS1997Biological Product (except Diagnostic) Manufacturing
SICCommercial Physical Research
SICPharmaceutical Preparations
SICCommercial Physical Research
SICMedicinals And Botanicals
SICDiagnostic Substances
SICBiological Prod's Not Diagnostic



  • Poslední aktualizace: 15.06.2021
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the Board, Co-FounderStelios Papadopoulos73
President, Chief Executive Officer, DirectorMichael Morrissey6015.07.2010
Chief Financial Officer, Executive Vice PresidentChristopher Senner5315.07.201515.07.2015
President - Product Development and Medical Affairs, Chief Medical OfficerGisela Schwab6411.02.2016
Executive Vice President - Scientific Strategy, Chief Scientific OfficerPeter Lamb6011.02.2016
Executive Vice President, General CounselJeffrey Hessekiel5210.02.2014
Executive Vice President - CommercialPatrick Haley45